|
| 36367998 | Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. | J Clin Oncol | 2023 |
| 37289025 | The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. | Cancer Res | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 34741653 | Delivering exercise medicine to cancer survivors: has COVID-19 shifted the landscape for how and who can be reached with supervised group exercise? | Support Care Cancer | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35643841 | Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. | Eur J Cancer | 2022 |
| 35688679 | A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. | Clin Genitourin Cancer | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35389288 | Quality of Life of Prostate Cancer Survivors Participating in a Remotely Delivered Web-Based Behavioral Intervention Pilot Randomized Trial. | Integr Cancer Ther | 2022 |
| 35446278 | Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer: Benefit or Caution? | Am J Clin Oncol | 2022 |
| 36109521 | Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. | Nat Commun | 2022 |
| 36267196 | Functional impact of androgen-targeted therapy on patients with castration-resistant prostate cancer. | BJUI Compass | 2022 |
| 36251389 | The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. | Cancer Res | 2022 |
| 35142815 | Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2022 |
| 34518652 | Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. | Prostate Cancer Prostatic Dis | 2022 |
| 34298717 | The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. | Cancers (Basel) | 2021 |
| 34884981 | The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. | Cancers (Basel) | 2021 |
| 34879873 | A pilot feasibility study of Exercising Together© during radiation therapy for prostate cancer: a dyadic approach for patients and spouses. | Pilot Feasibility Stud | 2021 |
| 34870399 | Examining developments in multicancer early detection: highlights of new clinical data from recent conferences. | Am J Manag Care | 2021 |
| 34767021 | Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. | JAMA Netw Open | 2021 |
| 34820369 | HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1α-Inhibition. | Front Cell Dev Biol | 2021 |
| 34461975 | Study protocol for the Exercising Together© trial: a randomized, controlled trial of partnered exercise for couples coping with cancer. | Trials | 2021 |
| 34742325 | Protocol for GET FIT Prostate: a randomized, controlled trial of group exercise training for fall prevention and functional improvements during and after treatment for prostate cancer. | Trials | 2021 |
| 34161051 | Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. | N Engl J Med | 2021 |
| 34129025 | Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial. | JAMA Netw Open | 2021 |
| 32424106 | Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. | Proc Natl Acad Sci U S A | 2020 |
| 32001144 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. | Eur Urol | 2020 |
| 31924316 | Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study. | Eur Urol | 2020 |
| 31745256 | Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. | Prostate Cancer Prostatic Dis | 2020 |
| 31830211 | Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. | JAMA Oncol | 2020 |
| 33200893 | Novel blood-based early cancer detection: diagnostics in development. | Am J Manag Care | 2020 |
| 33112397 | Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. | JAMA Netw Open | 2020 |
| 33382378 | Feasibility and Acceptability of a Remotely Delivered, Web-Based Behavioral Intervention for Men With Prostate Cancer: Four-Arm Randomized Controlled Pilot Trial. | J Med Internet Res | 2020 |
| 32624423 | Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. | Urol Oncol | 2020 |
| 32850444 | Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy. | Front Oncol | 2020 |
| 32986533 | Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. | JCO Oncol Pract | 2020 |
| 32727885 | Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2020 |
| 32616555 | A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. | J Immunother Cancer | 2020 |
| 32811715 | Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. | Eur Urol | 2020 |
| 32527692 | Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. | Eur Urol | 2020 |
| 27141017 | Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. | Ann Oncol | 2019 |
| 30224345 | Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2019 |
| 31320748 | Combining options in metastatic prostate cancer. | Nat Rev Urol | 2019 |
| 31196032 | A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). | BMC Cancer | 2019 |
| 31274110 | Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. | Eur Urol Oncol | 2019 |
| 30988096 | Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2019 |
| 30804427 | MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2019 |
| 30918106 | Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. | Mol Cancer Res | 2019 |
| 31171481 | Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. | Clin Genitourin Cancer | 2019 |